destiny pharma limited
destiny pharma limited Company Information
Company Number
03167025
Next Accounts
Sep 2025
Shareholders
undisclosed
william guy love
View AllGroup Structure
View All
Industry
Other research and experimental development on natural sciences and engineering
Registered Address
c/o cork gully llp, 40, villiers street, london, WC2N 6NJ
Website
www.destinypharma.comdestiny pharma limited Estimated Valuation
Pomanda estimates the enterprise value of DESTINY PHARMA LIMITED at £1m based on a Turnover of £831.6k and 1.24x industry multiple (adjusted for size and gross margin).
destiny pharma limited Estimated Valuation
Pomanda estimates the enterprise value of DESTINY PHARMA LIMITED at £0 based on an EBITDA of £-6.7m and a 5.66x industry multiple (adjusted for size and gross margin).
destiny pharma limited Estimated Valuation
Pomanda estimates the enterprise value of DESTINY PHARMA LIMITED at £18.7m based on Net Assets of £9.2m and 2.03x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Destiny Pharma Limited Overview
Destiny Pharma Limited is a live company located in london, WC2N 6NJ with a Companies House number of 03167025. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in March 1996, it's largest shareholder is undisclosed with a 26.8% stake. Destiny Pharma Limited is a mature, small sized company, Pomanda has estimated its turnover at £831.6k with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Destiny Pharma Limited Health Check
Pomanda's financial health check has awarded Destiny Pharma Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 5 areas for improvement. Company Health Check FAQs
3 Strong
1 Regular
5 Weak
Size
annual sales of £831.6k, make it smaller than the average company (£4.3m)
£831.6k - Destiny Pharma Limited
£4.3m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Destiny Pharma Limited
- - Industry AVG
Production
with a gross margin of 46.9%, this company has a comparable cost of product (46.9%)
46.9% - Destiny Pharma Limited
46.9% - Industry AVG
Profitability
an operating margin of -810.1% make it less profitable than the average company (3.6%)
-810.1% - Destiny Pharma Limited
3.6% - Industry AVG
Employees
with 22 employees, this is below the industry average (44)
22 - Destiny Pharma Limited
44 - Industry AVG
Pay Structure
on an average salary of £165.3k, the company has a higher pay structure (£64.5k)
£165.3k - Destiny Pharma Limited
£64.5k - Industry AVG
Efficiency
resulting in sales per employee of £37.8k, this is less efficient (£124k)
£37.8k - Destiny Pharma Limited
£124k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Destiny Pharma Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 326 days, this is slower than average (44 days)
326 days - Destiny Pharma Limited
44 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Destiny Pharma Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 431 weeks, this is more cash available to meet short term requirements (32 weeks)
431 weeks - Destiny Pharma Limited
32 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 7.7%, this is a lower level of debt than the average (44.4%)
7.7% - Destiny Pharma Limited
44.4% - Industry AVG
DESTINY PHARMA LIMITED financials
Destiny Pharma Limited's latest turnover from December 2023 is £831.6 thousand and the company has net assets of £9.2 million. According to their latest financial statements, Destiny Pharma Limited has 22 employees and maintains cash reserves of £6.4 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 831,552 | ||||||||||||||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | -6,735,994 | -7,776,344 | -6,286,951 | -6,552,512 | -5,584,752 | -6,083,857 | -3,221,850 | -1,449,803 | -1,204,627 | -1,708,106 | -712,142 | -1,216,490 | -1,521,015 | -1,524,122 | -1,897,369 |
| Interest Payable | 1 | ||||||||||||||
| Interest Receivable | 289,756 | 64,800 | 15,520 | 71,611 | 63,478 | 75,999 | 10,459 | 397 | 7,662 | 10,505 | 4,800 | 17,164 | 40,745 | 54,578 | 159,035 |
| Pre-Tax Profit | -6,446,238 | -7,711,544 | -6,271,431 | -6,480,901 | -5,521,274 | -6,007,858 | -3,211,391 | -1,449,406 | -1,196,965 | -1,697,601 | -707,342 | -1,199,326 | -1,480,270 | -1,469,545 | -1,738,334 |
| Tax | 789,202 | 1,207,975 | 931,951 | 1,069,824 | 813,250 | 841,144 | 233,908 | 191,578 | 181,932 | 303,276 | 86,414 | 164,168 | 217,424 | 208,136 | 234,169 |
| Profit After Tax | -5,657,036 | -6,503,569 | -5,339,480 | -5,411,077 | -4,708,024 | -5,166,714 | -2,977,483 | -1,257,828 | -1,015,033 | -1,394,325 | -620,928 | -1,035,158 | -1,262,846 | -1,261,409 | -1,504,165 |
| Dividends Paid | |||||||||||||||
| Retained Profit | -5,657,036 | -6,503,569 | -5,339,480 | -5,411,077 | -4,708,024 | -5,166,714 | -2,977,483 | -1,257,828 | -1,015,033 | -1,394,325 | -620,928 | -1,035,158 | -1,262,846 | -1,261,409 | -1,504,165 |
| Employee Costs | 3,636,776 | 3,567,598 | 2,939,029 | 2,245,557 | 2,025,085 | 2,278,118 | 1,721,201 | 505,292 | 482,236 | 440,806 | 445,796 | 550,270 | 638,847 | 638,622 | 630,695 |
| Number Of Employees | 22 | 23 | 21 | 17 | 16 | 15 | 12 | 8 | |||||||
| EBITDA* | -6,729,798 | -7,764,016 | -6,274,433 | -6,535,631 | -5,566,312 | -6,074,194 | -3,219,773 | -1,448,464 | -1,203,849 | -1,707,302 | -711,276 | -1,215,287 | -1,518,735 | -1,521,030 | -1,895,344 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 19,235 | 24,621 | 35,882 | 18,141 | 32,922 | 30,421 | 22,313 | 1,161 | 2,500 | 602 | 608 | 1,474 | 2,677 | 4,671 | 6,591 |
| Intangible Assets | 2,341,469 | 2,261,435 | 2,261,435 | 2,261,435 | |||||||||||
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 2,360,704 | 2,286,056 | 2,297,317 | 2,279,576 | 32,922 | 30,421 | 22,313 | 1,161 | 2,500 | 602 | 608 | 1,474 | 2,677 | 4,671 | 6,591 |
| Stock & work in progress | |||||||||||||||
| Trade Debtors | 18,947 | ||||||||||||||
| Group Debtors | |||||||||||||||
| Misc Debtors | 1,214,177 | 1,606,266 | 1,339,863 | 1,680,766 | 1,044,900 | 930,759 | 277,126 | 216,520 | 424,901 | 122,786 | 202,037 | 246,016 | 243,782 | 263,362 | |
| Cash | 6,382,603 | 4,903,461 | 4,645,562 | 9,744,217 | 7,479,642 | 7,060,821 | 11,724,037 | 1,481,492 | 1,118,574 | 2,004,021 | 537,266 | 912,121 | 1,951,787 | 3,173,738 | 4,632,454 |
| misc current assets | 5,036,406 | 5,059,641 | 205,142 | ||||||||||||
| total current assets | 7,596,780 | 6,509,727 | 5,985,425 | 11,424,983 | 8,524,542 | 13,027,986 | 17,060,804 | 1,698,012 | 1,342,663 | 2,428,922 | 660,052 | 1,114,158 | 2,197,803 | 3,417,520 | 4,895,816 |
| total assets | 9,957,484 | 8,795,783 | 8,282,742 | 13,704,559 | 8,557,464 | 13,058,407 | 17,083,117 | 1,699,173 | 1,345,163 | 2,429,524 | 660,660 | 1,115,632 | 2,200,480 | 3,422,191 | 4,902,407 |
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 395,428 | 172,543 | 218,156 | 725,593 | 513,508 | 403,552 | 151,582 | 57,881 | 39,156 | 301,856 | 74,441 | 67,961 | 88,328 | 50,348 | 95,469 |
| Group/Directors Accounts | |||||||||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 372,888 | 997,219 | 555,280 | 542,541 | 284,631 | 398,240 | 245,893 | 96,876 | 55,187 | 155,812 | 231,519 | 72,043 | 101,366 | 98,211 | 271,897 |
| total current liabilities | 768,316 | 1,169,762 | 773,436 | 1,268,134 | 798,139 | 801,792 | 397,475 | 154,757 | 94,343 | 457,668 | 305,960 | 140,004 | 189,694 | 148,559 | 367,366 |
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | |||||||||||||||
| total long term liabilities | |||||||||||||||
| total liabilities | 768,316 | 1,169,762 | 773,436 | 1,268,134 | 798,139 | 801,792 | 397,475 | 154,757 | 94,343 | 457,668 | 305,960 | 140,004 | 189,694 | 148,559 | 367,366 |
| net assets | 9,189,168 | 7,626,021 | 7,509,306 | 12,436,425 | 7,759,325 | 12,256,615 | 16,685,642 | 1,544,416 | 1,250,820 | 1,971,856 | 354,700 | 975,628 | 2,010,786 | 3,273,632 | 4,535,041 |
| total shareholders funds | 9,189,168 | 7,626,021 | 7,509,306 | 12,436,425 | 7,759,325 | 12,256,615 | 16,685,642 | 1,544,416 | 1,250,820 | 1,971,856 | 354,700 | 975,628 | 2,010,786 | 3,273,632 | 4,535,041 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | -6,735,994 | -7,776,344 | -6,286,951 | -6,552,512 | -5,584,752 | -6,083,857 | -3,221,850 | -1,449,803 | -1,204,627 | -1,708,106 | -712,142 | -1,216,490 | -1,521,015 | -1,524,122 | -1,897,369 |
| Depreciation | 6,196 | 12,328 | 12,518 | 16,881 | 18,440 | 9,663 | 2,077 | 1,339 | 778 | 804 | 866 | 1,203 | 2,280 | 3,092 | 2,025 |
| Amortisation | |||||||||||||||
| Tax | 789,202 | 1,207,975 | 931,951 | 1,069,824 | 813,250 | 841,144 | 233,908 | 191,578 | 181,932 | 303,276 | 86,414 | 164,168 | 217,424 | 208,136 | 234,169 |
| Stock | |||||||||||||||
| Debtors | -392,089 | 266,403 | -340,903 | 635,866 | 114,141 | 653,633 | 60,606 | 197,573 | -405,954 | 302,115 | -79,251 | -43,979 | 2,234 | -19,580 | 263,362 |
| Creditors | 222,885 | -45,613 | -507,437 | 212,085 | 109,956 | 251,970 | 93,701 | 18,725 | -262,700 | 227,415 | 6,480 | -20,367 | 37,980 | -45,121 | 95,469 |
| Accruals and Deferred Income | -624,331 | 441,939 | 12,739 | 257,910 | -113,609 | 152,347 | 149,017 | 41,689 | -100,625 | -75,707 | 159,476 | -29,323 | 3,155 | -173,686 | 271,897 |
| Deferred Taxes & Provisions | |||||||||||||||
| Cash flow from operations | -5,949,953 | -6,426,118 | -5,496,277 | -5,631,678 | -4,870,856 | -5,482,366 | -1,394,045 | -979,288 | -1,554,433 | -379,655 | -1,056,830 | -1,262,410 | -1,512,121 | -1,557,171 | |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | |||||||||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | 289,756 | 64,800 | 15,520 | 71,611 | 63,478 | 75,999 | 10,459 | 397 | 7,662 | 10,505 | 4,800 | 17,164 | 40,745 | 54,577 | 159,035 |
| cash flow from financing | 7,509,939 | 6,685,084 | 427,881 | 10,159,788 | 274,212 | 813,686 | 18,129,168 | 1,551,821 | 301,659 | 3,021,986 | 4,800 | 17,164 | 40,745 | 54,577 | 6,198,241 |
| cash and cash equivalents | |||||||||||||||
| cash | 1,479,142 | 257,899 | -5,098,655 | 2,264,575 | 418,821 | -4,663,216 | 10,242,545 | 362,918 | -885,447 | 1,466,755 | -374,855 | -1,039,666 | -1,221,951 | -1,458,716 | 4,632,454 |
| overdraft | |||||||||||||||
| change in cash | 1,479,142 | 257,899 | -5,098,655 | 2,264,575 | 418,821 | -4,663,216 | 10,242,545 | 362,918 | -885,447 | 1,466,755 | -374,855 | -1,039,666 | -1,221,951 | -1,458,716 | 4,632,454 |
destiny pharma limited Credit Report and Business Information
Destiny Pharma Limited Competitor Analysis
Perform a competitor analysis for destiny pharma limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in WC2N area or any other competitors across 12 key performance metrics.
destiny pharma limited Ownership
DESTINY PHARMA LIMITED group structure
Destiny Pharma Limited has 1 subsidiary company.
Ultimate parent company
DESTINY PHARMA LIMITED
03167025
1 subsidiary
destiny pharma limited directors
Destiny Pharma Limited currently has 7 directors. The longest serving directors include Dr William Love (Jun 1996) and Mrs Debra Barker (Jan 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr William Love | 62 years | Jun 1996 | - | Director | |
| Mrs Debra Barker | 62 years | Jan 2020 | - | Director | |
| Mr Aled Williams | 55 years | Jun 2022 | - | Director | |
| Mr Nigel Brooksby | England | 74 years | Jun 2022 | - | Director |
| Mr James Stearns | 45 years | Jun 2022 | - | Director | |
| Sir Nigel Rudd | 78 years | Jul 2023 | - | Director | |
| Mr Christopher Tovey | 59 years | Sep 2023 | - | Director |
P&L
December 2023turnover
831.6k
0%
operating profit
-6.7m
-13%
gross margin
46.9%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
9.2m
+0.2%
total assets
10m
+0.13%
cash
6.4m
+0.3%
net assets
Total assets minus all liabilities
destiny pharma limited company details
company number
03167025
Type
Private limited with Share Capital
industry
72190 - Other research and experimental development on natural sciences and engineering
incorporation date
March 1996
age
29
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
destiny pharma plc (September 2024)
destiny pharma holdings limited (August 2017)
See moreaccountant
-
auditor
CROWE UK LLP
address
c/o cork gully llp, 40, villiers street, london, WC2N 6NJ
Bank
NATIONAL WESTMINSTER BANK PLC
Legal Advisor
OSBORNE CLARKE LLP COVINGTON & BURLING LLP
destiny pharma limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to destiny pharma limited. Currently there are 0 open charges and 2 have been satisfied in the past.
destiny pharma limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for DESTINY PHARMA LIMITED. This can take several minutes, an email will notify you when this has completed.
destiny pharma limited Companies House Filings - See Documents
| date | description | view/download |
|---|
